We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Alternative Names:
ENPAXIQ; Epjevy; ONX-0803; Pacritinib; Pacritinib citrate; Pacritinibum; SB-1518
Latest Information Update: 16 Dec 2019
Price :
$50
*
Adis is an information provider.
We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
Originator
S*BIO
Developer
Cardiff University; CTI BioPharma; National Cancer Research Institute; Ohio State University Comprehensive Cancer Center; S*BIO; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
Class
Antineoplastics; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Yes
-
Myeloproliferative disorders; Myelofibrosis
New Molecular Entity
Yes
Highest Development Phases
Phase III
Myelofibrosis
Phase II
Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Phase I/II
Graft-versus-host disease
Phase I
Haematological disorders
Preclinical
Chronic myeloid leukaemia
Suspended
Colorectal cancer
Discontinued
Lymphoma
Most Recent Events
03 Feb 2020
CTI BioPharma announces intention to submit NDA to US FDA for Myelofibrosis in early 2022
07 Dec 2019
Safety and efficacy data from the phase II PACIFICA trial in Myelofibrosis presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
28 Jul 2019
No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in USA (PO, Capsule)
Restricted Access
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.
Login
with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
